The announcement launches an effort at Harvard Medical School to begin studying treatments for newly forming viral infections, specifically those caused by coronaviruses and ones that lead to hemorrhagic fever. The cataclysmic nature of the COVID-19 pandemic reinforced the need for scientists to prepare for the next public health crisis.

AbbVie will provide $30 million over three years, as well as support from its scientists, expertise, and facilities, to advance collaborative research and early-stage development across the following five programs:

• Immunity and immunopathology
• Small molecules
• Host targeting for antiviral therapies
• Antibody therapeutics
• Translational development

News report highlights risk of infectious disease research
Incidents with exposure to lab-created coronaviruses highlight the risks of working with pathogens, even in highly secure research facilities, according...

Study analyzes how SARS-CoV-2 undermines immune defenses
A new research study used whole-genome sequencing to analyze the genetic profile of patients with the SARS-CoV-2 virus to gain more insight into how it...

Human-infecting coronaviruses have lived in bats for decades
Genome sequencing of the SARS-CoV-2 virus has revealed that the type of virus family to which the novel coronavirus belongs most likely first emerged...

How has SARS-CoV-2 evolved from bat coronavirus?
Structural comparison between a bat coronavirus and SARS-CoV-2 reveals specific characteristics that make the new virus more pathogenic, according to...

New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek...